Pacira Biosciences Inc Stock Price, News & Analysis

Pacira BioSciences (NASDAQ: PCRX) announced it will present findings from its Phase 1 study of PCRX-201, a gene therapy candidate for knee osteoarthritis, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) on May 15, 2025. The presentation will focus on how neutralizing antibodies (NAbs) affect the therapy's efficacy, safety, and potential for redosing.

Dr. MiJeong Kim, Senior Director of Translational Sciences, will deliver the presentation titled "Understanding the Clinical Immunogenicity of Locally Injected HCAd Vector Provides Insight into Optimizing Dosing Strategy." Additionally, Pacira will host a symposium on High-Capacity Adenoviral Vectors (HCAd) for common diseases, featuring speakers from Baylor College of Medicine and Pacira's development team.

Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after U.S. markets close.

Key details:

• Conference Call Time: 4:30 p.m. ET
• Participation Options: Live conference call and webcast
• Access Method: Pre-registration required for Q&A telephone participation
• Alternative Access: Live audio webcast available through "Events" page on investor.pacira.com
• Replay Availability: Webcast recording accessible for approximately two weeks post-call

Pacira BioSciences (Nasdaq: PCRX) has announced promising two-year efficacy data for its gene therapy candidate PCRX-201 in treating knee osteoarthritis. The study, presented at the 2025 OARSI World Congress, demonstrated sustained improvements in knee pain, stiffness, and function across all severity levels following a single injection.

The Phase 1 trial involved 72 patients aged 30-80, with two cohorts receiving different treatment protocols. The corticosteroid-pretreated cohort showed superior results with 48-65% pain reduction and 53-72% stiffness reduction, compared to 41-58% pain and 33-53% stiffness reductions in the non-pretreated group.

No serious treatment-related adverse events were reported. The most common side effect was joint swelling, occurring in 36% of pretreated patients versus 61% of non-pretreated patients. PCRX-201 received FDA's RMAT designation in March 2024 and EMA's ATMP designation in May 2023. A Phase 2 study (ASCEND) is currently underway.

Pacira BioSciences (Nasdaq: PCRX) has announced the upcoming presentation of new 104-week efficacy data for their gene therapy candidate PCRX-201 (enekinragene inzadenovec) at the 2025 OARSI World Congress in Incheon, South Korea.

The presentation, titled 'Improvements in Pain, Stiffness, and Function After a Single Intraarticular Injection of Gene Therapy PCRX-201 for Knee Arthritis Osteoarthritis: A Subgroup Analysis by Structural Severity,' will be delivered by Professor Ali Mobasheri from the University of Oulu and State Research Institute Centre for Innovative Medicine.

The data demonstrates results following a single local administration for patients with mild to severe osteoarthritis of the knee. The presentation is scheduled for April 25 and 26, 2025, from 3:30-4:15 PM KST.

Pacira BioSciences (NASDAQ: PCRX) has announced a significant $300 million share repurchase program, receiving support from DOMA Perpetual Capital Management, which owns 4.2% of the company's outstanding shares.

The initiative, representing the largest buyback in Pacira's history, comes alongside a new emphasis on increasing pre-tax net income margins. DOMA Perpetual views these moves as reflecting Pacira's strong financial position and the Board's commitment to disciplined capital allocation.

According to Pedro Escudero, CEO of DOMA Perpetual, Pacira has entered a period of rapid growth, with scaling earnings and free cash flow enabling capital returns while maintaining investment in growth. DOMA Perpetual believes the stock is currently undervalued relative to both its historical average and future growth potential.

Pacira BioSciences (PCRX) has announced strategic actions to enhance shareholder value, including a $300 million share repurchase authorization through December 2026. The company outlined its '5x30' strategy goals for 2030, which include:

• Treating over 3 million patients annually
• Achieving double-digit revenue growth rate
• Improving gross margins by 5 percentage points over 2024
• Expanding clinical pipeline with 5 novel programs
• Establishing 5 new pipeline and commercial partnerships

The company emphasized its EXPAREL exclusivity runway extending to 2039, providing long-term visibility for strategy execution. Management remains focused on operational efficiency and margin expansion at the pre-tax net income level to enhance shareholder value.

Pacira BioSciences (PCRX) has granted inducement awards to 18 new employees on April 2, 2025, under its Amended and Restated 2014 Inducement Plan. The awards include:

• Stock options for 23,100 shares granted to 9 employees, with a 10-year term and exercise price of $24.89 per share
• Restricted stock units (RSUs) for 43,400 shares granted to 18 employees

The stock options follow a four-year vesting schedule with 25% vesting after the first year and quarterly installments over the following 36 months. RSUs vest annually in four equal installments starting April 1, 2026. All awards require continued employment and were approved by the People & Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

Pacira BioSciences (NASDAQ: PCRX) has announced a settlement of patent litigation with Fresenius Kabi USA and other companies regarding EXPAREL® (bupivacaine liposome injectable suspension). The settlement grants Fresenius two key licenses:

1. A volume- license starting in early 2030, beginning with high-single-digit percentage of U.S. market volumes, gradually increasing to the high thirties percentage by the final three years.

2. An unlimited volume license beginning no earlier than 2039.

The agreement comes before the July 2, 2044 expiration of Pacira's last Orange Book-listed EXPAREL patent. The settlement resolves all outstanding claims and includes Consent Judgments filing with various U.S. Courts to prevent Fresenius from marketing generic versions before the agreed terms.